Detalles de la búsqueda
1.
Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes.
Lipids Health Dis
; 15(1): 116, 2016 Jul 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27405296
2.
The effects of laropiprant on the antiplatelet activity of co-administered clopidogrel and aspirin.
Platelets
; 25(7): 480-7, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24206527
3.
Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia.
Am Heart J
; 162(4): 708-16, 2011 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-21982664
4.
Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
Am Heart J
; 157(2): 352-360.e2, 2009 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-19185645
5.
Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes.
Am Heart J
; 156(5): 826-32, 2008 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-19061694
6.
Incidence of hypersensitivity and anaphylaxis with sugammadex.
J Clin Anesth
; 47: 67-73, 2018 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-29621739
7.
Effects of Age, Sex, and Obesity on the Single-Dose Pharmacokinetics of Omarigliptin in Healthy Subjects.
Clin Pharmacol Drug Dev
; 5(5): 374-82, 2016 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27627193
8.
Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics of rosiglitazone.
Clin Pharmacol Drug Dev
; 4(1): 56-62, 2015 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27128003
9.
Efficacy and Tolerability of Sitagliptin Compared with Glimepiride in Elderly Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control: A Randomized, Double-Blind, Non-Inferiority Trial.
Drugs Aging
; 32(6): 469-76, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-26041585
10.
Overtreatment and undertreatment with anticoagulation in relation to cardioversion of atrial fibrillation (the RHYTHM-AF study).
Am J Cardiol
; 113(3): 480-4, 2014 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24332698
11.
Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia.
Int J Cardiol
; 167(1): 225-31, 2013 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-22305632
12.
Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency.
Diabetes Care
; 36(5): 1067-73, 2013 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-23248197
13.
Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
Am J Cardiovasc Drugs
; 12(3): 197-206, 2012 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22500948
14.
Identification of genes affecting apolipoprotein B secretion following siRNA-mediated gene knockdown in primary human hepatocytes.
Atherosclerosis
; 222(1): 154-7, 2012 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-22398276
15.
Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia.
J Clin Lipidol
; 6(3): 235-43, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22658147
16.
A comparison of the natriuretic and kaliuretic effects of cicletanine and hydrochlorothiazide in prehypertensive and hypertensive humans.
J Hypertens
; 30(4): 819-27, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22278145
17.
Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide.
Diabetes Res Clin Pract
; 93(1): e15-7, 2011 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-21477878
18.
Safety of extended-release niacin/laropiprant in patients with dyslipidemia.
J Clin Lipidol
; 4(2): 105-112.e1, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-21122637
19.
Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.
Am J Cardiol
; 104(1): 74-81, 2009 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19576324
20.
Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors.
Cardiol Clin
; 26(4): 547-60, 2008 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-19031552